Purpose/Objective: Intensity Modulated Radiotherapy (IMRT) allows dose to be sculpted around target volumes, maintaining dose to the tumour whilst reducing dose to normal tissues. However, uptake of IMRT for lung cancer remains low, as a result of the paucity of clinical data and concerns about the impact of the low dose bath on toxicity. The Christie has treated 650 lung cancer patients with IMRT since 2008. Here we report the results of 106 patients, focusing on toxicity. Survival will be reported at a later date. Materials and Methods: A retrospective review of the first 106 patients receiving 6MV inversely planned (6-8 field)
Step and Shoot IMRT for lung cancer from 2008-2012 was carried out. A database was interrogated to correlate planning parameters with toxicity. Results: 106 patients with a median age of 67 (36-85) were included. Patients received a dose of 50-68 Gy in 20-33 fractions. Seventy three (69%) had non-small cell lung cancer, 23 (22%) small cell lung cancer, 3 (3%) mixed histology and 6 (6%) no histology. At presentation, 2 (2%), 17 (16%), 82 (77%) and 4 patients (4%) had stage I, II, III and IV disease. Treatment modalities were split evenly between concurrent (36%), sequential (33%) chemo-radiotherapy and radiotherapy alone (31%). Mean PTV volume was 586 cc (113.7-1297.2). Mean lung V20, V10 and V5 were 27.9% (7.9-35.3), 50.9% (13.4-83.1) and 64.8% (17.9-98.9). Fifty-two patients (49%) had V5 values > 65%. Mean dose to the oesophagus was 2462 cGy (482-5102); oesophageal V55 and V35 were 4.2% (0-70.8) and 37.6% (0-79.8). Heart V30 and V5 were 23.5% (0-60.6) and 57.6% (1.7-100). Acute G3 pneumonitis and oesophagitis were observed in 4 (3.8%) and 18 (17.1%) patients respectively. Late toxicity was not available in all patients. 5/76 (6.8%) developed late G3 pneumonitis and G3 dyspnoea, late G2 cough was reported in 7/75 (9.7%). Grade 1 and 2 pulmonary fibrosis occurred in 35/86 (41%) and 4/86 (5%) patients. Oesophageal stricture was evident in 3/83 (4%) and 1 patient developed an oesophageal fistula. There was no significant correlation between lung V5 and acute or late lung toxicity, using >65% as a cut off. Similarly, lung toxicity did not correlate with lung V10. There was also no relationship between mean oesophageal dose/V35/V55 and fistula or oesophageal stricture. Increase in PTV volume appeared to be significantly associated with grade of acute oesophagitis, but this trend was not observed when late oesophagitis or acute/late pneumonitis were examined. Conclusions: From our experience, IMRT to the thorax is well tolerated, with minimal grade 3 toxicity. Contrary to reports, we did not observe a correlation between lung V5 and acute/late lung toxicity however this data needs to be confirmed with a larger number of patients. Data will be updated prior to the ESTRO meeting.
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PET CT use and the occurrence of elective nodal failure in involved field radiotherapy for non-small cell lung L. Kepka 1 , J. Socha 2 1 SP ZOZ MSW Warmia@Mazury Oncology Centre, Radiotherapy, Olsztyn, Poland 2 Regional Cancer Centre, Radiotherapy, Czestochowa, Poland Purpose/Objective: Current guidelines do not recommend the use of elective nodal irradiation for NSCLC, for several reasons. One of these is that PET-CT provides adequate mediastinal nodal staging; thus, the involved field radiotherapy is all the more justified. We present a systematic review that compared the published rates of elective nodal failures (ENFs), which were defined as regional failures that occur without simultaneous or previous local recurrence in patients who did or did not undergo PET-CT for staging. Materials and Methods: Reports of the occurrence of ENFs were considered. Only studies that used involved fields and specified the number of ENFs in patients with and without PET-CT use were included. A chi-squared test was used for the comparison of the risk of ENF in patients who were staged with and without PET. Results: In total, 65 studies that reported the occurrence of ENF after radiotherapy for NSCLC were found. Finally, 48 studies were included and 2158 patients with and 1485 patients without PET-CT performed before radiotherapy were identified. There were 136 (6.3%) and 98 (6.6%) ENFs in patients with and without PET-CT, respectively (p = .74). The proportion of patients who were treated with SBRT was higher in the group with PET-CT (71%) than it was in the group without PET-CT (20%; p < .001). In the group of patients who were treated with SBRT without PET-CT, there were 19 (6.5%) ENFs compared with 106 (6.9%) ENFs in SBRT patients with PET-CT (p = .82). After excluding patients who were treated with SBRT, we detected 79 ENFs (6.6%) in 1192 patients without PET-CT, and 30 (4.9%) ENFs in 617 patients with PET-CT performed before radiotherapy (p=.16).
Conclusions:
The failure to reduce ENF by PET-CT was demonstrated. These data should be regarded in the context of the adequacy of reporting the rate of ENF and of the clinical relevance of the reported rates.
